Table 1.

Postmenopausal hormone (PMH) use and intraocular pressure (IOP)

	Study Design	Number of treated patients/ control patients	IOP associated with no PMH use (Mean ± STD) mm Hg	IOP associated with PMH use (Mean ± STD) mm Hg	Change in IOP (mm Hg)	Months on PMH therapy	Type of PMH
Affinito⁴²	Prospective controlled randomized study	25/25	16.1 ± 2.3	14.1 ± 2.0	−2	3	E+P
Altintas⁴³	Prospective study with age matched controls	20/24	16.2± 2.3	12.3±1.8	−3.8	2	E or E+P
Cocksuer⁴⁴	Prospective	34/0	14.1±2.8	13.4±2.7	−0.7	6	E+P
Sator⁴⁵	Prospective study	25/0	16.2 ± 2.4 OS 15.3 ± 2.3 OD	14.0 ± 2.0 OS 13.8 ± 1.9 OD	−2.2 OS −1.5 OD	3	E+P
Tint ⁴⁶	Prospective cross sectional study	91/172	13.3 ± 2.9	11.85 ± 2.65	−1.7		E or E+P
Treister⁴⁷	Prospective	15/15	-	-	−2.0 -1.8	6	E E+P
Uncu⁴⁸	Prospective study	30/0	14.6 ± 0.8	12.6 ± 0.68	−2.0	12	E or E+P
Abramov⁴⁹	Prospective controlled cross sectional study	107/107	15	16	−1	≥12	E or E+P
Guaschino⁵⁰	Prospective controlled randomized study	40/40	14.8±3.2	14.9 ±4.3	−0.1	12	E+P
Toker⁵¹	Retrospective cohort study	30/32	13.3 ± 2.3	13.6 ±2.5	−0.3	48 (average)	E+P

Abbreviations used: E = estrogen, E+P = combined estrogen and progesterone; STD = standard deviation